PR Newswire
BOULDER, Colo., Nov. 20, 2018
BOULDER, Colo., Nov. 20, 2018 /PRNewswire/ -- Array
BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will
speak at the 30th Annual Piper Jaffray Healthcare Conference in New York. The public
is welcome to participate in the conference through a webcast on the Array BioPharma website.
About Array BioPharma
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and
commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and
other high-burden diseases. Array markets in the United States BRAFTOVI®
(encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with
unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Array's lead
clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor
indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional
programs being advanced by Array or current license-holders, including the following programs currently in registration trials:
selumetinib (partnered with AstraZeneca), larotrectinib and LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with
Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Ganovo® (danoprevir, partnered with Roche) was
recently approved in China for the treatment of viral hepatitis C. For more information on
Array, please visit www.arraybiopharma.com or follow
@arraybiopharma on Twitter and LinkedIn.
CONTACT:
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-30th-annual-piper-jaffray-healthcare-conference-300753401.html
SOURCE Array BioPharma Inc.